0001193125-21-331813.txt : 20211117 0001193125-21-331813.hdr.sgml : 20211117 20211117060657 ACCESSION NUMBER: 0001193125-21-331813 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211115 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211117 DATE AS OF CHANGE: 20211117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 211418356 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 8-K 1 d257656d8k.htm 8-K 8-K
false 0000875045 0000875045 2021-11-15 2021-11-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 15, 2021

 

Biogen Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   0-19311   33-0112644
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)

Registrant’s telephone number, including area code: (617) 679-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class

 

  

 

Trading Symbol(s)

 

  

 

Name of each exchange on which registered

 

    

Common Stock, $0.0005 par value

 

  

BIIB

 

  

The Nasdaq Global Select Market

 

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 15, 2021, Biogen Inc. (the “Company”) issued a press release announcing that Alfred W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company, effective December 31, 2021.

A copy of the Company’s press release is being furnished as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits

The exhibits listed below are furnished as part of this Current Report on Form 8-K

 

 Exhibit Number

       

Description

99.1

     

Biogen’s press release dated November 15, 2021

104

      Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Biogen Inc.
  By:  

  /s/ Wendell Taylor

   
      Wendell Taylor   
      Chief Corporation Counsel and Assistant Secretary   

Date: November 17, 2021

 

3

EX-99.1 2 d257656dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

 

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

CAMBRIDGE, Mass., November 15, 2021 — Biogen Inc. (Nasdaq: BIIB) announced today that Alfred “Al” W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the Company effective December 31, 2021. A 23-year veteran of Biogen, Dr. Sandrock, 64, led the development of many of the Company’s most important and transformational therapies in neurological diseases, including Tysabri® (natalizumab), Tecfidera® (dimethyl fumarate), Spinraza® (nusinersen), Plegridy® (peginterferon beta-1a) and Aduhelm™ (aducanumab-avwa). Dr. Sandrock served on Biogen’s Executive Committee since 2015, as Head of Research & Development since October 2019, and as Chief Medical Officer from 2012 to 2020.

Priya Singhal, M.D., M.P.H., Head of Global Safety and Regulatory Sciences, also with oversight responsibility for Japan and China R&D, will assume Dr. Sandrock’s duties as Head of Research & Development on an interim basis until a permanent successor is identified.

“Al is a visionary who has dedicated his life to helping patients confronting the most devastating diseases and is one of the most recognized drug developers of his generation,” said Michel Vounatsos, Chief Executive Officer at Biogen. “He inspired a new generation of scientists while helping to grow Biogen from a small biotech firm in Cambridge to a Fortune 500 enterprise, providing life-saving and life-changing treatments to patients all around the world. Among his multiple achievements, Al has built what I believe is the most talented neuroscience R&D team in the industry and a leading pipeline with approximately 30 clinical programs, including 10 programs in Phase 3 or filed.”

“During his tenure, Al spearheaded the development of many of Biogen’s most important pioneering therapies: Plegridy, Tysabri, and Tecfidera to treat multiple sclerosis, Spinraza, our groundbreaking treatment for spinal muscular atrophy, and Aduhelm, the first new treatment for Alzheimer’s disease in nearly 20 years. We are grateful for his outstanding leadership, intelligence, and passion to help society, and wish him all the best.”

Stelios Papadopoulos, Chairman of the Biogen Board of Directors, said: “Al is highly regarded and respected within Biogen and across the scientific community for his remarkable ability to combine rare intellect with warmth, humility, and empathy. His rare ability to see what others have overlooked and his tenacious drive to help others embodies what we strive to be as a company. The entire Board wishes to acknowledge with deep gratitude his tremendous contributions during his distinguished career.”

Dr. Sandrock said: “I have been honored to work alongside the many outstanding professionals helping to advance Biogen’s vital mission to develop innovative therapies for people living with serious neurological disorders. I am very proud of the Biogen R&D team, and I look forward to the new breakthroughs the company will achieve in the future.”

About Biogen

As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need.

In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.

The company routinely posts information that may be important to investors on its website at www.biogen.com. To learn more, please visit www.biogen.com and follow Biogen on social media –Twitter, LinkedIn,  Facebook, YouTube.

Biogen Safe Harbor

This news release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to our business activities; our strategy and plans and the potential of our commercial business and pipeline programs; capital allocation and investment strategy. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: our dependence on sales from our products; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our growth and strategic initiatives; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; the occurrence of adverse safety events; delay in approval of our drug candidates; product liability claims; third party collaboration risks; and direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the SEC. These statements are based on our current beliefs and expectations and speak only as of the date of this

news release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

###

 

MEDIA CONTACT(S):

Biogen

Ashleigh Koss

+ 1 908 205 2572

public.affairs@biogen.com

   

INVESTOR CONTACT(S):

Biogen

Mike Hencke

+1 781 464 2442

IR@biogen.com

 EX-101.SCH 3 biib-20211115.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 biib-20211115_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 biib-20211115_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g257656g1117051438461.jpg GRAPHIC begin 644 g257656g1117051438461.jpg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end XML 7 d257656d8k_htm.xml IDEA: XBRL DOCUMENT 0000875045 2021-11-15 2021-11-15 false 0000875045 8-K 2021-11-15 Biogen Inc. DE 0-19311 33-0112644 225 Binney Street Cambridge MA 02142 (617) 679-2000 false false false false Common Stock, $0.0005 par value BIIB NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 15, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000875045
Document Type 8-K
Document Period End Date Nov. 15, 2021
Entity Registrant Name Biogen Inc.
Entity Incorporation State Country Code DE
Entity File Number 0-19311
Entity Tax Identification Number 33-0112644
Entity Address, Address Line One 225 Binney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 679-2000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0005 par value
Trading Symbol BIIB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d257656d8k.htm biib-20211115.xsd biib-20211115_lab.xml biib-20211115_pre.xml d257656dex991.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d257656d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d257656d8k.htm" ] }, "labelLink": { "local": [ "biib-20211115_lab.xml" ] }, "presentationLink": { "local": [ "biib-20211115_pre.xml" ] }, "schema": { "local": [ "biib-20211115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "biib", "nsuri": "http://www.biogenidec.com/20211115", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d257656d8k.htm", "contextRef": "duration_2021-11-15_to_2021-11-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d257656d8k.htm", "contextRef": "duration_2021-11-15_to_2021-11-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.biogenidec.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-21-331813-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-331813-xbrl.zip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

W35S^542"Q/X3P3Y.<1I7^[H\*>E'^*G/1,RZ??CV,+!7T,NI]FZ+0I11\LJ M#OXP&!./#K%*8(((>\L)E^E"B HP0(.P[Q+ILCX->IBQP8G,X>>X ^9RAB&, M,=,!C?M"P@[]-0F=PHN_=^2M XIB99\X8.W)W\*SSUAZ?B!/9F*55_89=[=K MVUDT @H$-\R\)&CM3>&9\P'SFXOU-0K*TEVEVZ?@%5ZX[VM[92]% MT(L/X^H+S;R;LST7^$6C^;!XZQ#8_LZK//D-R\5!0#IT#&9O'R=RSS,D7P-C MO-"T:;S.T^<;;=X/;>I]SGJD/GT##L$W6"D6F)+!I5(<#TYH]+8DTU2.7XE\ MJ>AGJ7XYWC_AC&\;K,['Y">3F#SZ>\5;Q37QUEG>OD+:O&#ZXO]02P,$% M @ VS!Q4R85*CQ-$0 K#, !$ !D,C4W-C4V9&5X.3DQ+FAT;>U;:W/; M.++]KBK]!Y1R=RJIE17)B9/X$=>5+4^L7;_*5I([]QM$0A+6),$%2"O*K]_3 M#5"B;.?AB;W[9:>FQC9$ HW&Z=.G&YJ]X]'IR?[>\5%_L-]L[(V&HY.C_:/_ MV]C>[O3V7OH_,?XR/"#V#LX'?XB##X?G)^>7[UN?CX>CH]:^:#;PT*'*"F7W M]P;#3^)J],?)T?O67,?%;.==9TMG+2$3/MQ(U*5H\UT7U6"KM5&<;AIDL=._'/9/6J)_,OQP]KYE]72& M!?8.]H^^S/18%X(V(_9>'NSOO;S8KRU;FW,3<]ZRXHX1K?W?LK'+=VD6;/=; MUM_S'KD';PQ//XBKR\/WK>GFUMLW6V^FO5[O;7>K]_K5N]=O>IU_Y%/:Q.A] MZ^3\P[EWT:,97)LET9G:F"ERT\Z;3O='$]%*8V-C9:L1O(3'A#.)CL6S;O?M M5K3]$\YAFW]PMKWOGVW$$,/A_GY^-A(!A$L+<.0'VDQ5)OI99LHL4D[TDXE5 ML?C<$5&P?WIP.1Q\.&J+4^EMM]7:]B>R=.F;JB]RVHU7S8[<[F<"(CY4?AUFT]_+CNWN_V$?K[;O7-$ MV'YG@/]>S/C'3YY16\QUD@CKSW9B38HUE3@T:2ZSA5"3B8H*?:/P3L1.]?.\ MZGDW=D1?W-KF?*8+M>%R&:F=S,RMS%O[FZ\V%K B^$7<**!29F2>=UQ;#&S' MS[S:TYO7;9&0)V!/7$,5WDK)-ORLF4I>>;/K1&I<(72:&UM(/(S91(&UW,38 M5!;:9#*AUV"6!MQU)C)56I.8J8[P2:SA+:=<&Y]$21GK;"I&"R?'5N]=?;RX M=9B,B7=;?]G%CFQ!$VPP:>\ U@APJZ:(;[RV+YYGLL!'7\M4CE^TQ4A%$PV& MD#SIGYKR@6\*_];S6*>JF"T2,8$I5A8*UESE.K/RJ_S%'98.1&F=RC#E1:*F M5L>+/[\_\3Q7( 0 9:*LR<1:D-Z'L;$JY$9/OJA 1B??C\N92M*';PSD\&II MB(S+2&9T=!OR9BY?=.ZB53AE;X!5&.H17<'QZ(N*2@X@X#351:&4@)\BA? A M+GH F_K7SJ/"( SI]>TV;Q)3',ZTFHA3%3.(SR<3'>$1CF8\M]EL@+X1KMV. MJ-'Q_8+B5]CXPNJ%%%<(FIE,*CXZ[5QTCFN$]"$Q8QAY)2>J6/ &+M6T3&1A M[$)<15I1'L+.$F? 3<5,@,VMH^P+EG*YR1Q$2J+Q+D):_$TB^'D6^""3XI+] M-O"TUFP@(92INGM>U?'$.!O0P -.P=!J@H&I4S&63CM19H5.A!2Y L=D?%9E MA%TX&(B/$>EX8*)5W+FM4![)\55JH-5DLW&C'1$=_#F?&3'#[F*&1@&$SO!( MHB>*,CIB(R>&RT&,,-&)R&0 #8S%('$KDRFX5[I"\F#%C^QQS&0R5?$P/VM5 M9*89;(U%;,MIQ=LX0'J,UD9L@/>(B-LAD3D)672J(U@C/B'[R<(9 ,!C>A4_ M%:J1$'V(=4)&/%8X#IL(5(5VV""((U'+?<,%4VOF83X? M+U*X5"(CCK4I5#03$VU32A.',D42B*?L."E^1WXIL?FM;E>PR,HM7-,6N34W MFM,&.7G#R1OZG;S%?T$$G_;FQB8 33\U>(6\ MEY9)H7-L049P#V0.O=6&0F@VZ)C'I4X*;!(^&HJQ2N@1.J;E^2 )D;6QSWK. M1UL5-*)0DO=*C^LL+EUA?81*)&+)N\IUKD@0^]"4.?;[12.QJF0A7G5%A,^8 M@S ^M3)=2Z2][G*85KF Q4J\$@B2"4XE[@0\/)%4]& 9E%8'7Q8J*ZTBYPF7 M(^9GV.+WY<8ZM=]2&CG0II0-H>/UQ$Y>RD Z/09"\NC;39QHX]VKY*DQ1%O=@4).=<1GX%!*,8I:8A)F? $Y%53%B"+ MS(< >=2ZF<[;S)@),BP!SMN4@YPI0@,18=\&>"R"Q7/M9I@PY9 @J\?*%76( M/#Z+7L%";9RX0$Z)36[*Q/.0U$3K%<\%LC@PTG+"&(!XD),M'B4FVQ%U,IXA M;\%MD#5X&N"BG5$6PQLJYAC26;,1IN1(BW#R/F #;8'UP,MI6F95SB,W6X4] M7LLQ44%(A_ CGAM3<%HZ&N]QK.1C=2YM6LS:8E:F_+QWLX)XAA[LB&.:E%ZK M3><@5IA,#"$:NY&@$TK'B3'783:8V=% M>*S9&'-!*L*9F5-'$L(FQ:V:=%UAW] ;#7L#+TGATK@&!F M,F.Y_B/VOP;\P?T.7.%)G)FH%F(@U(GB.()@JB M8#J )3,WDA/MJCHBL.7*4+Y)-"A$-!@*+EYG3B1(EXG@B*N:Z889KIS$=% (HO6T,6K'+6I"S Z+?R MR,O!\!/T;NBV-1N"_]W+@<)%HM:/6*5W3IB&YI_M87>_/F%^J[*DZ[9J(KO($/:U>J 4L2BOUW!TWFZ:$Y!\1BX#8H6TRK"%)%KPEK9SZC (!'BZ1^H-C.8"H2?KV0OFU*%E\^L M4U_A! 69T5*+@%N\W5[R_5R2JVD MLZ\HCE!601I %F@K_JZR#*6\."VME8'-SU :)@)EV%=BR(S*(%E+V2U2L!0Q^9#-GUGCF9 &-D6LHML9I ME?HZ9^9/ UOYEMKI5(Z@6HJ*4$J^RD::^C@0[*L#]H)=Y4 "E^55]")Z2L4N0%5")0IPJ1 ,LZ!\ M_EE"YG2H\,<8PJYZJ!HXP3KNUUI'4J<<*3CC% OZ+B0>JG[II"N:V(O6N]B M4LG,]2N"B8HZR!23)')LPJ@G-*O@NXS9PY$&\A_5DO]21D;L,10K%"@D :%G MO3-(36!Q%2C6E3D%?+-!M&1#5ZN2G\Q]3P.?42VU(]M#GU%%F1O'J%XV;WU< MI'(!L52KO6AO&4Z+9#B%H:927XT=0 8J"3W']MJ)SE#5#+.'VT R\[&L^!V<.(8<_D]ZX@]3 MCLJQ>N!=UH][R^]^2:(&+%+G6!Q+"S)\.J$ZHD(1%0B+01^I5$]*,&U5IVQ0 MT4*IGIJC526E=&7B)*9@LGGF+6>%9O M3,S^!B.LS%6^4]]Q9$7Q,JIT+U,>QG?8 < M?VNDE6VZ$X8444Z\D$[J!CM7 QM 5U^YL-% 2.=CE)?$N. M%#3!JQ[3RW!KL^RB.IGT7,$8W^&8BE6.(U?!44Y2_<;7"?1ASG50@1 A*W1$ M!9._>S9CVD-U0Y#2?JJ_8^A38@6NA.64KQ9T5#UJ4;F,P3)J64&M+S21.BDM MBSX,%M0$9,U+2HILI-".92';JRYAZ;OV$)[A6LX#B(:L5@7=)O%7A>X[@#KW MW#]AE+ 6IE=]%9M-B8]6TW!-1KVN#0)J=8%&3@H] /9_HE&#^V(+16($"<]= MO:6IM'U@((LU=D?BWU*9H/V]/]=C.@H*FIRFOOA6X/V>(^I1.(+EER" &HH) MZHQ"[U-GEAO_U;+\.*]5-:2H1ZL*]_T#"EN=E(1*Q?==B@Q' 9=0(4\3K3@- M/*@R%+2%"QS-5UAT%T/JW1.LCFJEDMLEE/O@\9$"1M%<1%7Q 6OEZNJFL*SS M0,!$!F-Z+$_"[2&'Q]@!FWPU8OG&D-KC?'O+;[+3:\?G+PX03U-U:PU77R2W MU%I@L["OFF54S-GP/F8&$W54-'#)=%8$AG$7U= (4L'8&C M98MP,;Y\J=[W6X9)9?+JYIX1!8NJ6VY^,\O(?J .5&V!4K[IH9HTG&+@)3]& MR_@^/]]V^@J>5KPZ.JP$42WG46]G#-U)/:YF@Y;V8"W\O>[$G]&:@Y@!/^45;^AIU_^#D2!P>G9Q<7?0/AVZ+?[[HC\85'\'O&R_ 5P.SB\' M1Y<\'$SP(QO V$G_XNIHI_KEGAW=+8%O[9# QW9=[H=?!M7J6P KPF8T6'WR M*;SM][?"=?7@^@2OMZMQ_.>RME2UD5I4:2:O'7EC="Q^9B/[MTP*7_U[[-NB M>[]-?'HT&/8Q>C;J'XZ>7[W8^6$[X-^Q=]1 M@#W))OXJ>F*[^TYL=K?$YM;;S8?MH_>SKOIXY\!\G\?S5$=.H$6M^]]ZOS < MW$=V;1W$M[ >XKB*YF\^)\[./U_VGP(']T)Q>/;IZ&IT?OD--#X^5N[ \=$W M>JJ1:XZA5:_5TVSAKSWQ]EU/O'[S6FR^?KWYH$W\,A2'ES^ 7^!*_*!4P2B[ M1\# ^^>#/S#(_Y?.OP!02P$"% ,4 " #;,'%3#^5(?TL# """P $0 M @ $ 8FEI8BTR,#(Q,3$Q-2YX&UL4$L! A0#% @ VS!Q4[KSRDZY! #"L !4 M ( !#0H &)I:6(M,C R,3$Q,35?<')E+GAM;%!+ 0(4 Q0 ( -LP M<5.L=AVY/0\ --= . " ?D. !D,C4W-C4V9#AK+FAT M;5!+ 0(4 Q0 ( -LP<5,F%2H\31$ *PS 1 " 6(> I !D,C4W-C4V9&5X.3DQ+FAT;5!+!08 !0 % $ ! #>+P ! end